DEPDC1B Antibody

Product Specifications

Background

The DEP domain-containing 1B (DEPDC1B) protein was initially identified as a radiation response biomarker in human lymphoblastoid cell lines (1) . Like the related protein DEPDC1A, expression of DEPDC1B correlates with a poor prognosis in cancer patients (2,3) . Studies have shown that DEPDC1B levels are upregulated in non-small cell lung cancer (NSCLC) and have an inverse correlation with patient survival. Ectopic expression of DEPDC1B in NSCLC activated Wnt/B-catenin signaling and enhanced cell migration and invasion while silencing DEPDC1B expression suppressed these traits (2) .

NCBI Gene ID

55789

Swiss Prot

Q8WUY9

Accession Number

NP_060839

Host

Rabbit

Reactivity

Human

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer, Cell Cycle

Purification

DEPDC1B antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1204 - K562 Cell Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Mouse: (94%), Chicken: (88%)

Buffer

DEPDC1B antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

DEPDC1B antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Fragment

IgG

Specificity

DEPDC1B antibody is human specific. At least two isoforms are known to exist; this antibody will only detect the largest isoform. DEPDC1B antibody is predicted to not cross-react with DEPDC1A.

Symbol

DEPDC1B

Positive Control 2

Cat. No. 10-901 - Human Spleen Tissue Slide

NCBI Official Name

DEP domain containing 1B

NCBI Organism

Homo sapiens

Background Reference 01

Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010; 20:1482-92.

Background Reference 02

Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/B-catenin signaling. Biochem. Biophys. Res. Commun. 2014; 450:899-905.

Background Reference 03

Kassambara A, Schoenhals M, Moreaux J, et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One 2013; 8:e62752.